Canaccord Genuity Analysts Give Regeneron Pharmaceuticals, Inc. (REGN) a $522.00 Price Target

Canaccord Genuity set a $522.00 price objective on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in a research report report published on Monday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

REGN has been the subject of a number of other reports. Vetr downgraded Regeneron Pharmaceuticals from a sell rating to a strong sell rating and set a $368.84 target price for the company. in a research report on Monday, May 15th. Robert W. Baird downgraded Regeneron Pharmaceuticals from a neutral rating to an underperform rating and set a $408.00 target price for the company. in a research report on Tuesday, August 1st. Zacks Investment Research downgraded Regeneron Pharmaceuticals from a strong-buy rating to a hold rating in a research report on Tuesday, July 4th. Credit Suisse Group downgraded Regeneron Pharmaceuticals to a hold rating and set a $485.00 target price for the company. in a research report on Friday, July 14th. Finally, Piper Jaffray Companies reissued an overweight rating and issued a $557.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, August 1st. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Regeneron Pharmaceuticals presently has a consensus rating of Hold and an average target price of $495.59.

Regeneron Pharmaceuticals (NASDAQ REGN) opened at 466.075 on Monday. Regeneron Pharmaceuticals has a one year low of $325.35 and a one year high of $543.55. The firm has a market capitalization of $49.42 billion, a price-to-earnings ratio of 46.757 and a beta of 1.66. The firm has a 50-day moving average price of $490.71 and a 200-day moving average price of $430.04.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, topping the Zacks’ consensus estimate of $2.67 by $1.50. The business had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. Regeneron Pharmaceuticals’s quarterly revenue was up 21.2% compared to the same quarter last year. During the same period last year, the company posted $2.82 earnings per share. Analysts expect that Regeneron Pharmaceuticals will post $14.85 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.com-unik.info/2017/08/18/canaccord-genuity-analysts-give-regeneron-pharmaceuticals-inc-regn-a-522-00-price-target.html.

In other news, Director Joseph L. Goldstein sold 1,000 shares of the stock in a transaction on Friday, June 9th. The stock was sold at an average price of $482.55, for a total transaction of $482,550.00. Following the transaction, the director now directly owns 14,000 shares of the company’s stock, valued at approximately $6,755,700. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Robert E. Landry sold 526 shares of the stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $472.19, for a total value of $248,371.94. Following the transaction, the senior vice president now directly owns 9,099 shares in the company, valued at $4,296,456.81. The disclosure for this sale can be found here. Insiders have sold a total of 56,922 shares of company stock worth $27,383,105 over the last three months. Insiders own 10.40% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the company. Alpha Windward LLC boosted its position in shares of Regeneron Pharmaceuticals by 0.3% in the second quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 1 shares in the last quarter. Concert Wealth Management Inc. boosted its position in shares of Regeneron Pharmaceuticals by 0.4% in the first quarter. Concert Wealth Management Inc. now owns 723 shares of the biopharmaceutical company’s stock worth $269,000 after buying an additional 3 shares in the last quarter. Cleararc Capital Inc. boosted its position in shares of Regeneron Pharmaceuticals by 0.3% in the first quarter. Cleararc Capital Inc. now owns 1,850 shares of the biopharmaceutical company’s stock worth $717,000 after buying an additional 5 shares in the last quarter. Regentatlantic Capital LLC boosted its position in shares of Regeneron Pharmaceuticals by 0.9% in the second quarter. Regentatlantic Capital LLC now owns 537 shares of the biopharmaceutical company’s stock worth $264,000 after buying an additional 5 shares in the last quarter. Finally, Sheaff Brock Investment Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 1.4% in the first quarter. Sheaff Brock Investment Advisors LLC now owns 750 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 10 shares in the last quarter. 67.16% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

What are top analysts saying about Regeneron Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Regeneron Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit